Nuvectis Pharma Targets a $9.8 Billion Oral PNH Market With Late-Stage NXP100
Nuvectis Pharma (NASDAQ: NVCT) has reinvented itself almost overnight. Once known primarily for a single mid-stage oncology drug, the company vaulted into the rare-disease arena in June when it licensed two new assets from Haisco Pharmaceutical Group, and it now heads toward late-stage regulatory review with a differentiated lead candidate.
A Transformative Licensing Deal
Rather than build slowly from its oncology roots, Nuvectis moved decisively. The company secured worldwide rights outside China to NXP100, a potentially best-in-class once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), along with a second oncology asset, NXP200. In exchange, Nuvectis agreed to pay $40 million upfront plus up to $1.42 billion in milestone payments, most of which trigger only if the programs hit specific development, regulatory, and commercial targets down the road.
Why the Phase 3 Data Stands Out
The deal draws its strength from the clinical numbers behind NXP100. In a head-to-head Phase 3 trial against eculizumab, the infused therapy that has anchored PNH treatment for nearly two decades, NXP100 delivered striking results. Specifically, 59.5% of patients on NXP100 achieved a transfusion-free normal hemoglobin response, compared with just 8.3% on eculizumab. In other words, the oral candidate outperformed the entrenched standard by more than seven-fold on the endpoint that most directly shapes first-line treatment decisions.
That advantage matters clinically, not just cosmetically. Because a missed dose in PNH can trigger a dangerous breakdown of red blood cells, a reliable once-daily pill taken at home addresses both convenience and adherence, two factors that carry real weight in this disease.
A Concrete Regulatory Catalyst
Investors also have a timeline to watch. Two NXP100 marketing authorization applications already sit under review with China’s National Medical Products Administration, and first approval decisions could arrive within the next six to twelve months. Consequently, Nuvectis now carries a defined regulatory catalyst on the calendar for late 2026 or early 2027, and additional readouts stack on top of it, including new NXP900 oncology data expected this summer and future NXP200 results.
A Market the Street Is Already Rewarding
Meanwhile, the broader backdrop reinforces the setup. Grand View Research projects the global PNH treatment market will nearly double, climbing from $5.75 billion in 2024 to roughly $9.8 billion by 2030 as oral therapies gain ground. Novartis’s Fabhalta, the first approved oral Factor B inhibitor and NXP100’s closest comparison, illustrates that momentum, posting $169 million in Q1 2026 sales and more than doubling year-over-year.
Furthermore, dealmakers have repeatedly paid up in 2026 for simpler-dosing profiles. Vertex agreed to acquire Crinetics for about $10 billion, Jade Biosciences drew a valuation above $1.3 billion, and TG Therapeutics climbed past an $8 billion market cap. Taken together, these transactions suggest the market treats reduced dosing friction as genuine value rather than a footnote.
What Comes Next
Looking ahead, Nuvectis enters the second half of 2026 with a fuller pipeline and several near-term catalysts. The company now holds a late-stage rare-disease asset in regulatory review, a second oncology program in NXP200, and a licensing partner in Haisco that has also signed sizable deals with Eli Lilly and AbbVie over the past year. For a company defined until recently by a single oncology drug, this marks less an incremental update than a genuine reinvention on the same ticker.
